Annexon appoints commercial executive William 'BJ' Jones to board of directors

Annexon, Inc.

William 'BJ' Jones appointed to Board as Class I director effective Jan 9, 2025, term through 2027 annual meeting.
Receives $40K annual retainer, initial 88K-share option (3-yr monthly vest), and 44K-share annual option.
Jones brings 30 years commercial launch experience; currently CCO at NewAmsterdam Pharma; previously at Biohaven (acquired by Pfizer for $11.6B).
Company notes his expertise valuable as ANX005 (Guillain-Barré Syndrome) and ANX007 (geographic atrophy) approach commercialization.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

William Jones

Director

ANNX · Annexon, Inc.

Effective: 2025-01-09
Filed: January 10, 2025, 6:59 PM ET

On January 9, 2025, the Board of Directors (the “Board”) of Annexon, Inc. (the “Company”) appointed William Jones, to the Board, effectively immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

William Jones was appointed as Director at Annexon, Inc..

Action: appointed
Role: Director

Exact text from the filing

On January 9, 2025, the Board of Directors (the “Board”) of Annexon, Inc. (the “Company”) appointed William Jones, to the Board, effectively immediately.

View on SEC.gov

Annexon, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-004133

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.